Survey data detailing impact of OFF time & dyskinesia in people affected by Parkinson’s disease presented at American Acade...
April 19 2021 - 9:15AM
Business Wire
Parkinson & Movement Disorder Alliance (PMD Alliance,
www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq:
ADMS), a company dedicated to developing and delivering medicines
that make a meaningful difference to people affected by
neurological diseases, today announced findings from a survey on
the impact of OFF time and dyskinesia, also known as Parkinson’s
disease (PD) motor complications, presented at the American Academy
of Neurology (AAN) Annual Meeting, by Jill Farmer, D.O., M.P.H..
The survey, co-sponsored by PMD Alliance and Adamas
Pharmaceuticals, was conducted by PMD Alliance, and the results
were based on 775 respondents, including 527 people with
Parkinson’s and 248 care partners.
“These survey findings highlight what I’ve consistently seen in
my practice treating people with Parkinson’s disease,” said Jill
Giordano Farmer, D.O., M.P.H., Assistant Professor of Neurology at
Drexel College of Medicine and Director of Parkinson’s Disease and
Movement Disorder Program at Global Neuroscience Institute. “Many
people experience significant disruption in their daily activities
due to OFF and dyskinesia. As a result, patients will often
withdraw from social activities and experience a more significant
emotional impact than we may realize. It’s important for people
with Parkinson’s and their care partners to be proactive and start
the conversation about motor complications with their doctors. We
can help patients identify OFF periods and dyskinesia, and ways to
maximize good ON time to make the most of their day.”
Key survey findings
- PD motor complications are common with 76% (n=591) of
respondents reporting OFF and 51% (n=398) reporting dyskinesia; 48%
(n=368) of respondents reported experiencing both OFF and
dyskinesia.
- Despite the frequency of motor complications 78% of people with
Parkinson’s and care partner respondents report an incomplete
understanding of OFF and dyskinesia and their relationship to
levodopa.
- Importantly, for respondents who experience motor
complications, they happen often. Between 86% and 90% reported the
presence of these problems daily and over 60% of respondents
changed plans and activities due to these PD motor
complications.
- Ultimately, for many respondents, PD motor complications were
found to be unpredictable, make social interactions difficult, and
lead to feelings of loneliness and isolation.
The survey was conducted online with the PMD Alliance membership
and included 775 respondents, comprising 527 people with
Parkinson’s and 248 care partners. Questions included basic
demographic and disease state information, presence and frequency
of OFF or dyskinesia, and their impact on social interactions and
activities.
“The more we understand the true impact and prevalence of PD
motor complications, the better we can serve people living with
this disease stay socially and physically active,” said Adrian
Quartel, M.D., Chief Medical Officer, Adamas. “These data highlight
the widespread burden and impact of OFF and dyskinesia in daily
living. While many studies are typically confined to specific
clinic populations, this survey is unique since PMD Alliance is a
national advocacy organization with broad reach whose respondents
better reflect the diversity within the community.”
About Parkinson’s disease, OFF and dyskinesia
Parkinson’s disease (PD) is a progressive, neurodegenerative
disorder caused by the gradual loss of brain cells that produce the
neurotransmitter dopamine and affects approximately one million
people in the United States. Dopamine decline in the brain results
in a wide range of motor (movement-related) and non-motor symptoms.
As the disease progresses, people taking levodopa-based therapy are
likely to experience reemergence or sudden return of stiffness,
rigidity and tremors, referred to as OFF episodes between
medication doses, that may be unpredictable. The primary treatment
for PD is with levodopa; however, over time levodopa may lead to
involuntary, uncontrolled movements known as dyskinesia. The abrupt
and unpredictable transitions between episodes of dyskinesia,
normal movement, and OFF lead to considerable impact on patients’
lives.
About Parkinson & Movement Disorder Alliance
Parkinson & Movement Disorder Alliance is an independent,
national nonprofit dedicated to providing opportunities for people
to learn, live more fully and spark meaningful connections around
them. PMD Alliance serves people across the United States and is
not affiliated with any medical practice or institution. PMD
Alliance is committed to keeping our community safe and healthy. To
learn more about the organization visit www.PMDAlliance.org.
About Adamas
At Adamas our vision is clear – to deliver innovative medicines
that reduce the burden of neurological diseases on patients,
caregivers and society. We are a fully integrated company focused
on growing a portfolio of therapies to address a range of
neurological diseases. For more information, please visit
www.adamaspharma.com.
Source: Adamas Pharmaceuticals, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210419005187/en/
Media Contacts: Sarah Mathieson Vice President of
Corporate Communications 510-450-3528
smathieson@adamaspharma.com
Amanda Nelson Manager, Public Relations at PMD Alliance
520-664-7951 amanda@pmdalliance.org
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024